The Life Sciences IPOs + Capital Markets team advised the underwriters of SQZ Biotechnologies Company’s (NYSE: SQZ) initial public offering of 5,073,529 shares of common stock at a public offering price of $16 per share, including full exercise of the underwriters’ option to purchase an addition 661,764 shares of common stock to cover over-allotments. The gross proceeds of the offering were approximately $81 million before deducting underwriting commissions and estimated offering expenses.
SQZ is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions.
The Goodwin team was led by Mitch Bloom, Marishka DeToy and Patty Shields, and included Julie Tibbets, Elizabeth Mulkey, Nikhil Sethi, Duncan Greenhalgh, Olivia Uitto, Roger Cohen, Sarah Bock, Janet Andolina and Matt Dunay.
For more details, please read the press release and an article in Fierce Biotech.